Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma

BACKGROUND: Proteasome inhibitor Carfilzomib (CFZ) is effective in treating patients with refractory or relapsed multiple myeloma (MM) but has been associated with cardiovascular adverse events (CVAE) such as hypertension, cardiomyopathy, and heart failure. This study aimed to investigate the contri...

Descripción completa

Detalles Bibliográficos
Autores principales: Tantawy, Marwa, Yang, Guang, Algubelli, Raghunandan Reddy, DeAvila, Gabriel, Rubinstein, Samuel M., Cornell, Robert F., Fradley, Michael G., Siegel, Erin M., Hampton, Oliver A., Silva, Ariosto S., Lenihan, Daniel, Shain, Kenneth H., Baz, Rachid C., Gong, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319068/
https://www.ncbi.nlm.nih.gov/pubmed/37408649
http://dx.doi.org/10.3389/fcvm.2023.1181806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319068/
https://www.ncbi.nlm.nih.gov/pubmed/37408649
http://dx.doi.org/10.3389/fcvm.2023.1181806

Ejemplares similares